Updated:
Zenas BioPharma
Zenas BioPharma is a asset manager based in Waltham; the Altss profile covers its classification, headquarters, registration, AUM band, and key contacts for...
General information
Firm type
Asset Manager
Location
Region
North America
Country
United States
City
Waltham
Corporate office
852 Winter Street Suite 250, Waltham, MA 02451, United States
Principals
Lonnie Moulder
Chief Executive Officer and Chairman of the Board of Directors
Sector focus
Frequently asked questions
Who makes investment decisions at Zenas BioPharma?
Lonnie Moulder serves as CEO and Chairman, leading corporate strategy and development. The board includes executives such as Patricia Allen, James Boylan, Patrick Enright, Hongbo Lu, Jake Nunn, and John Orloff. (per firm website)
What is Zenas BioPharma's primary therapeutic focus?
The firm concentrates exclusively on autoimmune diseases with significant unmet medical need. Its two lead candidates target B-cell activity and BTK pathways to address multiple indications. (per firm website)
Is Zenas BioPharma structured as a family office or a standalone biotech?
Zenas BioPharma operates as a biopharmaceutical company, not a family office or investment firm. It conducts drug development and commercialization with a dedicated management team and board.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: